Ractigen Therapeutics Hits Milestone with First Patient Dosing in Phase II Trial of RAG-17 for ALS Treatment Ractigen Therapeutics has commenced the Phase II clinical trial of RAG-17, a novel siRNA therapy aimed at treating SOD1-ALS. The dosing of the first patient marks a significant step towards potential therapeutic advancements.

Ractigen Therapeutics Hits Milestone with First Patient Dosing in Phase II Trial of RAG-17 for ALS Treatment #China #ALS #Ractigen_Therapeutics #RAG-17 #Nantong

Ractigen's RAG-17 ALS Data Impresses at AAN 2025, Advances Phase I Trial Ractigen Therapeutics debuted RAG-17's promising ALS data at AAN 2025, receiving top honors and advancing its Phase I trial for SOD1-ALS.

Ractigen's RAG-17 ALS Data Impresses at AAN 2025, Advances Phase I Trial #China #ALS #Ractigen_Therapeutics #RAG-17 #Nantong

Ractigen Therapeutics' CEO Dr. Long-Cheng Li Wins 2024 Life Science Ice Breaking Award Dr. Long-Cheng Li, CEO of Ractigen Therapeutics, receives the 2024 Life Science Ice Breaking Award for his pioneering research in ALS treatments.

Ractigen Therapeutics' CEO Dr. Long-Cheng Li Wins 2024 Life Science Ice Breaking Award #China #ALS_Research #Ractigen_Therapeutics #Nantong,_Suzhou #Dr._Long-Cheng_Li

Ractigen Therapeutics Achieves Major Milestone in ALS Research with First Patient Dosed in Phase I Trial Ractigen Therapeutics has successfully dosed the first patient in a clinical trial for RAG-17 targeting ALS, marking a significant step in RNA therapy development.

Ractigen Therapeutics Achieves Major Milestone in ALS Research with First Patient Dosed in Phase I Trial #China #ALS #Ractigen_Therapeutics #RAG-17 #Nantong_and_Suzhou